A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel
Top Cited Papers
Open Access
- 15 January 2004
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 350 (3), 232-238
- https://doi.org/10.1056/nejmoa031859
Abstract
Whether the glycoprotein IIb/IIIa inhibitor abciximab is beneficial in patients undergoing elective percutaneous coronary intervention after pretreatment with clopidogrel is unknown.Keywords
This publication has 25 references indexed in Scilit:
- Clopidogrel for Coronary StentingCirculation, 2003
- Scientific and therapeutic advances in antiplatelet therapyNature Reviews Drug Discovery, 2003
- Clinical Implications of Percutaneous Coronary Intervention-Clopidogrel in Unstable angina to prevent Recurrent Events (PCI-CURE) StudyCirculation, 2002
- Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary RevascularizationNew England Journal of Medicine, 2001
- ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines)—Executive SummaryCirculation, 2001
- Defining the Optimal Activated Clotting Time During Percutaneous Coronary InterventionCirculation, 2001
- Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placementHeart, 2001
- A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery StentingNew England Journal of Medicine, 1998
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997
- A Randomized Comparison of Antiplatelet and Anticoagulant Therapy after the Placement of Coronary-Artery StentsNew England Journal of Medicine, 1996